An Experiment Comparing Public Reactions to the Labels "Community Immunity" Versus "Herd Immunity".
Community Immunity Versus Herd Immunity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Holly Witteman, PhD
- Phone Number: 418-656-2131
- Email: holly.witteman@fmed.ulaval.ca
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to use a computer
- Able to use the internet
- Able to read and respond to questions in English or French
- 18+ years old and living in Canada
Exclusion Criteria:
- Unable to view images on a computer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Herd immunity
|
Using the traditional term "herd immunity"
|
|
Experimental: Community immunity
|
In the intervention arm, participants are shown the less traditional term "community immunity" in place of the more traditional "herd immunity"
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Orientation towards protection of others
Time Frame: Immediately after the intervention
|
A measure of the extent to which people believe that individual vaccination behavior is important to protect others.
Question wording: "When a safe and effective vaccine exists that can prevent people from catching and passing on a contagious disease, it is important for people to get vaccinated to protect ..." Measured across two to three items (family, others in the community, people who are more vulnerable to disease) on a 7-point Likert-type scale (strongly disagree = 1, strongly agree = 7).
|
Immediately after the intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- commimm
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attitudes
-
NCT07102485Not yet recruiting
-
NCT01965743Completed
-
NCT02242890Completed
-
NCT02225171Completed
-
NCT02832856Completed
-
NCT02855593Active, not recruiting
-
NCT03938610Active, not recruitingKnowledge, Attitudes, Practice
-
NCT05645120CompletedKnowledge, Attitudes, Practice
-
NCT04617990UnknownKnowledge, Attitudes, Practice
-
NCT04184219CompletedKnowledge, Attitudes, Practice
Clinical Trials on Herd immunity
-
NCT07102485Not yet recruiting
-
NCT07503938CompletedPostmenopausal Endometriosis
-
NCT04649840Completed
-
NCT04777175Recruiting
-
NCT05492643Recruiting
-
NCT05667597Active, not recruitingCOVID-19 | SARS CoV 2 Infection
-
NCT02846220Completed
-
NCT06070961Active, not recruiting
-
NCT07528911CompletedEpithelial High Grade Serous Ovarian Cancer
-
NCT03737682Completed